134 related articles for article (PubMed ID: 21651496)
1. Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond.
Bologna M; Vicentini C; Muzi P; Pace G; Angelucci A
Curr Med Chem; 2011; 18(19):2827-35. PubMed ID: 21651496
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.
Ojemuyiwa MA; Madan RA; Dahut WL
Expert Opin Emerg Drugs; 2014 Dec; 19(4):459-70. PubMed ID: 25345821
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
5. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
6. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors.
Natoli C; Perrucci B; Perrotti F; Falchi L; Iacobelli S;
Curr Cancer Drug Targets; 2010 Aug; 10(5):462-83. PubMed ID: 20384577
[TBL] [Abstract][Full Text] [Related]
8. Nonreceptor tyrosine kinases in prostate cancer.
Chang YM; Kung HJ; Evans CP
Neoplasia; 2007 Feb; 9(2):90-100. PubMed ID: 17357254
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: a comparative review.
Ranieri G; Pantaleo M; Piccinno M; Roncetti M; Mutinati M; Marech I; Patruno R; Rizzo A; Sciorsci RL
Crit Rev Oncol Hematol; 2013 Nov; 88(2):293-308. PubMed ID: 23768779
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
Guo T; Ma S
ChemMedChem; 2021 Feb; 16(4):600-620. PubMed ID: 33179854
[TBL] [Abstract][Full Text] [Related]
11. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
12. Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.
Drenberg CD; Baker SD; Sparreboom A
Clin Pharmacol Ther; 2013 Mar; 93(3):215-9. PubMed ID: 23419484
[TBL] [Abstract][Full Text] [Related]
13. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
Tibes R; Trent J; Kurzrock R
Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
Cepero V; Sierra JR; Giordano S
Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
Teng Y; Cai Y; Pi W; Gao L; Shay C
J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer.
Kondapaka BS; Reddy KB
Mol Cell Endocrinol; 1996 Mar; 117(1):53-8. PubMed ID: 8734473
[TBL] [Abstract][Full Text] [Related]
18. Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells.
Telliez A; Desroses M; Pommery N; Briand O; Farce A; Laconde G; Lemoine A; Depreux P; Hénichart JP
ChemMedChem; 2007 Mar; 2(3):318-32. PubMed ID: 17206733
[TBL] [Abstract][Full Text] [Related]
19. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
Levitzki A; Klein S
Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11579-11586. PubMed ID: 31076554
[TBL] [Abstract][Full Text] [Related]
20. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
